Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 26, 2016 - Issue 1
Submit an article Journal homepage
707
Views
4
CrossRef citations to date
0
Altmetric
Reviews

Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014)

Yang YangFaculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan650500, China
,
Shu AnFaculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan650500, China
,
Ying LiuFaculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan650500, China
,
Xiao-Xi GuoFaculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan650500, China
,
Linghuan GaoFaculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan650500, China
,
Ji-Fu WeiResearch Division of Clinical Pharmacology, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing210029, China
&
Tian-Rui XuFaculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan650500, ChinaCorrespondence[email protected]
 show all
Pages 89-106 | Published online: 26 Nov 2015

Bibliography

•This review provided molecular and physiological perspectives of the 5-hydroxytryptamine (5-HT) system research.

•This review summarized the fundamental information for the 5-HT receptors.

•This review systematically summarized the receptors and ligands information about the 5-HT system.

•This database provides primary and up-to-date information for G-protein-coupled receptors (GPCRs), including 5-HT receptors.

  • Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto. US 8148417 B2. 2012.

•This patent provided usage of novel 5-HT2A receptor agonists and antagonists invented by Arena Pharmaceuticals for treatment of physical and mental disorders.

  • Wacker D, Wang C, Katritch V, et al. Structural features for functional selectivity at serotonin receptors. Science. 2013;340:615–619.
  • Jones MP, Nicholl D, Trakas K. Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia. Int J Clin Pharmacol Ther [Internet]. 2010;48:383–399. DrugBank. 2014; [cited 2015 Nov 1]. Available from: http://www.drugbank.ca/drugs/DB01267.
  • Clarke WP, Chavera TA, Silva M, et al. Signalling profile differences: paliperidone versus risperidone. Br J Pharmacol. 2013;170:532–545.
  • Marti-Solano M, Sanz F, Pastor M, et al. A dynamic view of molecular switch behavior at serotonin receptors: implications for functional selectivity. PLoS One. 2014;9:e109312.
  • Clarke WP, Berg KA. Use of functional assays to detect and quantify functional selectivity. Drug Discov Today Technol. 2010;7:e31–e36.
  • Huang XP, Setola V, Yadav PN, et al. Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment. Mol Pharmacol. 2009;76:710–722.
  • Jaffre F, Bonnin P, Callebert J, et al. Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy. Circ Res. 2009;104:113–123.
  • Shyu KG. Serotonin 5-HT2B receptor in cardiac fibroblast contributes to cardiac hypertrophy: a new therapeutic target for heart failure? Circ Res. 2009;104:1–3.
  • Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev. 1994;46:157–203.
  • Fletcher PJ, Rizos Z, Sinyard J, et al. The 5-HT2C receptor agonist Ro60-0175 reduces cocaine self-administration and reinstatement induced by the stressor yohimbine, and contextual cues. Neuropsychopharmacology. 2008;33:1402–1412.
  • Martin JR, Bos M, Jenck F, et al. 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther. 1998;286:913–924.
  • Di Matteo V, Di Giovanni G, Di Mascio M, et al. SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology. 1999;38:1195–1205.
  • Knight AR, Misra A, Quirk K, et al. Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004;370:114–123.
  • Gleason SD, Lucaites VL, Shannon HE, et al. m-CPP hypolocomotion is selectively antagonized by compounds with high affinity for 5-HT(2C) receptors but not 5-HT(2A) or 5-HT(2B) receptors. Behav Pharmacol. 2001;12:613–620.
  • Mbaki Y, Gardiner J, McMurray G, et al. 5-HT 2A receptor activation of the external urethral sphincter and 5-HT 2C receptor inhibition of micturition: a study based on pharmacokinetics in the anaesthetized female rat. Eur J Pharmacol. 2012;682:142–152.
  • Higgins GA, Sellers EM, Fletcher PJ. From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists. Trends Pharmacol Sci. 2013;34:560–570.
  • Bishop MJNB. New 5-HT2C receptor agonists. Expert Opin Ther Patents. 2003;13:1691–1705.
  • Lee J, Jung ME. 5-HT2C receptor modulators: a patent survey. Expert Opin Ther Pat. 2010;20:1429–1455.

••This review summarized the information in the patent literature before 2010 for the 5-HT2C receptor modulators, and provided molecular and physiological perspectives of related research.

  • Kimura Y, Hatanaka K, Naitou Y, et al. Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist. Eur J Pharmacol. 2004;483:37–43.
  • Ochi T, Sakamoto M, Minamida A, et al. Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423, a novel antipsychotic agent. Bioorg Med Chem Lett. 2005;15:1055–1059.
  • Beattie DT, Smith JA, Marquess D, et al. The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004;143:549–560.
  • Harada K, Aota M, Inoue T, et al. Anxiolytic activity of a novel potent serotonin 5-HT2C receptor antagonist FR260010: a comparison with diazepam and buspirone. Eur J Pharmacol. 2006;553:171–184.
  • Kennett GA, Wood MD, Glen A, et al. In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist. Br J Pharmacol. 1994;111:797–802.
  • Kennett GA, Wood MD, Bright F, et al. In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties. Br J Pharmacol. 1996;117:427–434.
  • Kennett GA, Wood MD, Bright F, et al. SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology. 1997;36:609–620.
  • Fox SH. Pimavanserin as treatment for Parkinson’s disease psychosis. Lancet. 2014;383:494–496.
  • Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383:533–540.
  • Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related therto. WO 2005012254 A1. 2005.
  • Raqualia Pharma Inc. Novel pyrazole-3-carboxamide derivative having 5-ht2b receptor antagonist activity. WO 2010058858 A1. 2010.

•This patent disclosed the work of Raqualia Pharma Inc. on devoloping 5-HT2B receptor antagonists and the medical indication of treating pain.

  • Arena Pharmaceuticals, Inc. Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto. WO 2008042388 A1. 2008.
  • Arena Pharmaceuticals, Inc. 3-Phenyl-pyrazole derivatives as modulators of the 5-HT2a serotonin receptor useful for the treatment of disorders related thereto. US 7884101B2. 2011.
  • Janssen Pharmaceutica NV. Heterocyclic tetracyclic tetrahydrofuran derivatives as 5ht2 inhibitors in the treatment of CNS disorders. WO 2006079637 A1. 2006.

•This patent is a representative of Janssen Pharmaceutica NV’s work on 5-HT2A and 2C receptors antagonists, and the use of these compounds for the treatment of CNS disorders.

  • Arena Pharmaceuticals, Inc. 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto. US 8785441 B2. 2014.
  • La Roche H, Gobbi L, Jaeschke G, et al. Benzoyl-piperidine derivatives as dual modulators of the 5-ht2a and d3 receptors. WO 2009019174 A1. 2009.
  • Janssen Pharmaceutica NV. Pyrimidine compounds as serotonin receptor modulators. WO 2007019083 A1. 2007.

•This patent is a representative of Janssen Pharmaceutica NV’s work on 5-HT2 receptors antagonists, and the selectivity of these compounds towards 5-HT2A, 2B and 2C receptor subtypes were displayed.

  • Arena Pharmaceuticals, Inc. Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a. US 20060229335 A1. 2006.

•This patent is a representative of Arena Pharmaceuticals’s work on development of Diarylamine and arylheteroarylamine pyrazole derivatives as 5-HT2A receptor ligands, and the most promising compounds in chemical and biological assays exhibited good properties.

  • lgmpharma Altanserin. 2014; [cited 2015 Feb 8]. Available from: http://www.lgmpharma.com/product/altanserin/.
  • Arena Pharm Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof. WO 1999052927 A1. 1999.
  • Arena Pharm Inc. Pyrazole derivatives which modulate human serotonin receptors. WO 2001029008 A1. 2001.
  • Arena Pharm Inc. 5ht2c receptor modulators. WO 2003086306 A3. 2003.
  • FDA News Release: FDA approves weight-management drug Qsymia. July 17, 2012; [cited 2015 Feb 8]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312468.htm.
  • Joo JK, Lee KS. Pharmacotherapy for obesity. J Menopausal Med. 2014;20:90–96.
  • Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto. US 20090186895 A1. 2009.
  • Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related therto. WO 2005012254. 2005.
  • Arena Pharmaceuticals, Inc. Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto. WO 2010062323 A2. 2010.
  • Arena Pharmaceuticals, Inc. Pharmaceutical compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto. WO 2007041409 A1. 2007.
  • Janssen Pharmaceutica NV. Pyrimidine compounds as serotonin receptor modulators. US 8618288 B2. 2013.
  • H. Lundbeck A/S. Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia. WO 2012176066 A1. 2012.
  • H. Lundbeck A/S. Method for treating cognitive deficits. US 20110207744 A1. 2011.

•This patent provided methods of novel 5-HT2A receptor agonists and antagonists invented by H. Lundbeck A/S for treatment of mental disorders.

  • H. Lundbeck A/S. 1-piperazino-1,2-dihydroindene derivatives. EP 0638073 A1. 1995.
  • H. Lundbeck A/S. Method of administration of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia. WO 2012175531 A1. 2012.
  • Lundbeck & Co As H, Tine Bryan Stensboel, Silke Miller. 4- [2- (4-methylphenylsulfanyd-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of ADHD, melancholia, treatment resistant depression or residual symptoms in depression. WO 2008113360 A2. 2008.
  • Hoffmann-La Roche Inc. serotonin 5-HT2a and dopamine D3 receptors modulators such as N-trans-{4-[2-(4-benzo[d]isoxazol-3-yl)-piperazin-1-yl)-ethyl]-cyclohexyl}-3-methoxy-propionamide, useful in the treatment of cognitive disorders, drug addiction, depression, anxiety, dementia and psychological disorders US 7858630 B2. 2010.

•This patent disclosed usage of novel 5-HT2A receptor ligands invented by Hoffmann-La Roche for treatment of mental disorders.

  • Athersys Reports Third Quarter 2014 Results. 2014; [cited 2015 Feb 8]. Available from: http://www.athersys.com/secfiling.cfm?filingID=1193125-14-406287&CIK=1368148.
  • Athersys Inc. Substituted azepine derivatives as serotonin receptor modulators. WO 2006004931 A2. 2006.
  • Biovitrum A, Nilsson B. Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor. WO 2002040456 A1. 2002.
  • Athersys Inc. Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulator. WO 06028961. 2006.
  • Athersys Inc. Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators. WO 07081299. 2007.
  • Merck Sharp & Dohme, Tamara L, Curtis NR, Gancia E, et al. Arylsulfonyl benzofused heterocycles as 5-ht2a antagonists. WO 2006100519 A1. 2006.
  • Merck Sharp & Dohme. Arylsulfonyl benzyl ethers as 5-ht2a antagonists. WO 2006097766 A1. 2006.
  • Eli Lilly and Co. 6-Substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists. WO 05082859; 2005
  • Eli Lilly and Co. 6-(2,2,2-Trifluoroethylamino)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a 5-HT2C receptor agonist. WO 05019180. 2005.
  • Eli Lilly and Co. 6-Substituted-2,3,4,5-tetrahydro-1Hbenzo[d]azepines as 5-HT2C receptor agonists. WO 07028082. 2007.
  • Lilly Industries Limited. 2-methyl-thieno-benzodiazepine. US 5229382 A. 1993.
  • Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14:87–96.
  • Lilly Industries Limited. Treating central nervous system disorders. US 5627178 A. 1997.
  • Eli Lilly and Company. Administering antidepressant and serotonin reuptake inhibitor. US 6147072 A. 2007.
  • Eli Lilly and Company. Such as Alzheimer’s disease, by administering olanzapine or salt thereof. US 6506746 B2. 2003.
  • Synthon Ip Inc. Synthesis of olanzapine and intermediates thereof. US 7329747 B2. 2008.
  • Teva Pharmaceutical Industries Ltd. Methods of synthesizing olanzapine. US 7425627 B2. 2008.
  • Apotex Pharmachem Inc. Processes for the synthesis of olanzapine. US 7863442 B2. 2011.
  • Geneva Pharmaceuticals, Inc. Crystal olanzapine with a melting point of 187-191 degrees c. US 6740753 B2. 2004.
  • U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof. US 7022698 B2. 2006.
  • KRKA, Tovarna Zdravil, D.D. Pharmaceutical formulation of olanzapine. US 20110319395. 2011.
  • Durgaprasad P, Satyanarayana T, Satyanarayana V, et al. Stable pharmaceutical compositions of olanzapine and process for their preparation. US 20120058185 A1. 2012.
  • Wyeth [Pfizer, Inc.]. [1,4]Diazepino [6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents. WO 03091250. 2003.
  • Study evaluating vabicaserin in subjects with schizophrenia. 2014; [cited 2015 Feb 8]. Available from: http://clinicaltrials.gov/ct2/show/results/NCT00563706?term=vabicaserin&rank=2.
  • Kelly J. Principles of CNS drug development: from test tube to patient. Chichester: Wiley; 2010.
  • Wyeth [Pfizer, Inc.]. Chromane and chromene derivatives and uses thereof. WO 06116165. 2006.
  • Wyeth [Pfizer, Inc.]. Dihydrobenzofuranyl alkanamines and pharmaceutical compositions containing them. WO 05040146. 2005.
  • Wyeth [Pfizer, Inc.]. Dihydrobenzofuranyl alkanamine derivatives as 5HT2C agonists. WO 05044812. 2005.
  • Wyeth [Pfizer, Inc.]. Dihydrobenzofuran derivatives and uses thereof. WO 06116150. 2006.
  • Wyeth [Pfizer, Inc.]. Benzodioxane and benzodioxolane derivatives and uses thereof. WO 06116158. 2006.
  • Wyeth [Pfizer, Inc.]. Benzodioxane derivatives and uses thereof. WO 08052096. 2008.
  • Wyeth [Pfizer, Inc.]. Benzoxathine and benzoxathiole derivatives and uses thereof. WO 08052078. 2008.
  • Wyeth [Pfizer, Inc.]. Substituted indolizines and derivatives as CNS agents. WO 6050007. 2006.
  • Pfizer Products, Inc. 5-HT2C receptor modulators. WO 06103511. 2006.
  • Pfizer, Inc. Pyrimido[4,5-d]azepine derivatives as 5-HT2 C agonists. WO 08117169. 2008.
  • Takeda Pharmaceutical Co. Ltd. Pyridooxazepine derivative and use thereof. WO 09063991. 2009.
  • Takeda Pharmaceutical Co. Ltd. Condensed pyridine derivative and use thereof. WO 09063992. 2009.
  • Takeda Pharmaceutical Co. Ltd. Fused pyridine derivative and use thereof. WO 09063993. 2009.
  • Takeda Pharmaceutical Co. Ltd. Fused heterocyclic compound and use thereof. WO 07132841. 2007.
  • Takeda Pharmaceutical Co. Ltd. Benzoxazepine derivatives and use thereof. WO 08108445. 2008.
  • Takeda Pharmaceutical Co. Ltd. Tricyclic heterocyclic compound and use thereof. WO 08007661. 2008.
  • Takeda Pharmaceutical Co. Ltd. Bicyclic heterocyclic compound and use thereof. WO 08007664. 2008.
  • Michael J, Bishop BMN. New 5-HT2C receptor agonists. Expert Opin Ther Pat. 2003;13:1691–1705.
  • Bromidge SM, Dabbs S, Davies DT, et al. Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent. J Med Chem. 2000;43:1123–1134.
  • Roth BL, Willins DL, Kristiansen K, et al. 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. Pharmacol Ther. 1998;79:231–257.
  • Bombardi C. Neuronal localization of the 5-HT2 receptor family in the amygdaloid complex. Front Pharmacol. 2014;5:68.
  • Muguruza C, Moreno JL, Umali A, et al. Dysregulated 5-HT(2A) receptor binding in postmortem frontal cortex of schizophrenic subjects. Eur Neuropsychopharmacol. 2013;23:852–864.
  • Aghajanian GK, Marek GJ. Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res. 1999;825:161–171.
  • Kihara H, Hirose K, Koganei H, et al. AT-1015, a novel serotonin (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2A receptors and prevents the laurate-induced peripheral vascular lesion in rats. J Cardiovasc Pharmacol. 2000;35:523–530.
  • Pasqualetti M, Ori M, Castagna M, et al. Distribution and cellular localization of the serotonin type 2C receptor messenger RNA in human brain. Neuroscience. 1999;92:601–611.
  • Wisler JW, Xiao K, Thomsen AR, et al. Recent developments in biased agonism. Curr Opin Cell Biol. 2014;27:18–24.
  • Rajagopal S, Ahn S, Rominger DH, et al. Quantifying ligand bias at seven-transmembrane receptors. Mol Pharmacol. 2011;80:367–377.
  • Sauliere A, Bellot M, Paris H, et al. Deciphering biased-agonism complexity reveals a new active AT1 receptor entity. Nat Chem Biol. 2012;8:622–630.
  • Busnelli M, Sauliere A, Manning M, et al. Functional selective oxytocin-derived agonists discriminate between individual G protein family subtypes. J Biol Chem. 2012;287:3617–3629.
  • Xu TR, Ward RJ, Pediani JD, et al. Intramolecular fluorescence resonance energy transfer (FRET) sensors of the orexin OX1 and OX2 receptors identify slow kinetics of agonist activation. J Biol Chem. 2012;287:14937–14949.
  • Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu Rev Med. 2013;64:393–406.
  • Gray JA, Roth BL. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull. 2007;33:1100–1119.
  • Weiner DM, Burstein ES, Nash N, et al. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther. 2001;299:268–276.
  • Ray TS. Psychedelics and the human receptorome. PLoS One. 2010;5:e9019.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.